Multi-resolution-test  ||| S:0 E:22 ||| JJ
for  ||| S:22 E:26 ||| IN
consistent  ||| S:26 E:37 ||| JJ
phenotype  ||| S:37 E:47 ||| JJ
discrimination  ||| S:47 E:62 ||| NN
and  ||| S:62 E:66 ||| CC
biomarker  ||| S:66 E:76 ||| JJ
discovery  ||| S:76 E:86 ||| NN
in  ||| S:86 E:89 ||| IN
translational  ||| S:89 E:103 ||| JJ
bioinformatics  ||| S:103 E:118 ||| NN
While  ||| S:118 E:124 ||| IN
high-throughput  ||| S:124 E:140 ||| JJ
technologies  ||| S:140 E:153 ||| NNS
are  ||| S:153 E:157 ||| VBP
expected  ||| S:157 E:166 ||| VBN
to  ||| S:166 E:169 ||| TO
play  ||| S:169 E:174 ||| VB
a  ||| S:174 E:176 ||| DT
critical  ||| S:176 E:185 ||| JJ
role  ||| S:185 E:190 ||| NN
in  ||| S:190 E:193 ||| IN
clinical  ||| S:193 E:202 ||| JJ
translational  ||| S:202 E:216 ||| JJ
research  ||| S:216 E:225 ||| NN
for  ||| S:225 E:229 ||| IN
complex  ||| S:229 E:237 ||| JJ
disease  ||| S:237 E:245 ||| NN
diagnosis ||| S:245 E:254 ||| NN
,  ||| S:254 E:256 ||| ,
the  ||| S:256 E:260 ||| DT
ability  ||| S:260 E:268 ||| NN
to  ||| S:268 E:271 ||| TO
accurately  ||| S:271 E:282 ||| VB
and  ||| S:282 E:286 ||| CC
consistently  ||| S:286 E:299 ||| RB
discriminate  ||| S:299 E:312 ||| JJ
disease  ||| S:312 E:320 ||| NN
phenotypes  ||| S:320 E:331 ||| NN
by  ||| S:331 E:334 ||| IN
determining  ||| S:334 E:346 ||| VBG
the  ||| S:346 E:350 ||| DT
gene  ||| S:350 E:355 ||| NN
and  ||| S:355 E:359 ||| CC
protein  ||| S:359 E:367 ||| NN
expression  ||| S:367 E:378 ||| NN
patterns  ||| S:378 E:387 ||| NNS
as  ||| S:387 E:390 ||| IN
signatures  ||| S:390 E:401 ||| NNS
of  ||| S:401 E:404 ||| IN
different  ||| S:404 E:414 ||| JJ
clinical  ||| S:414 E:423 ||| JJ
conditions  ||| S:423 E:434 ||| NNS
remains  ||| S:434 E:442 ||| VBZ
a  ||| S:442 E:444 ||| DT
challenge  ||| S:444 E:454 ||| NN
in  ||| S:454 E:457 ||| IN
translational  ||| S:457 E:471 ||| JJ
bioinformatics ||| S:471 E:485 ||| NN
.  ||| S:485 E:487 ||| .
In  ||| S:487 E:490 ||| IN
this  ||| S:490 E:495 ||| DT
study ||| S:495 E:500 ||| NN
,  ||| S:500 E:502 ||| ,
we  ||| S:502 E:505 ||| PRP
propose  ||| S:505 E:513 ||| VBP
a  ||| S:513 E:515 ||| DT
novel  ||| S:515 E:521 ||| NN
feature  ||| S:521 E:529 ||| NN
selection  ||| S:529 E:539 ||| NN
algorithm ||| S:539 E:548 ||| NNS
:  ||| S:548 E:550 ||| :
Multi-Resolution-Test  ||| S:550 E:572 ||| NNP
( ||| S:572 E:573 ||| -LRB-
MRT-test ||| S:573 E:581 ||| NNP
)  ||| S:581 E:583 ||| -RRB-
that  ||| S:583 E:588 ||| WDT
can  ||| S:588 E:592 ||| MD
produce  ||| S:592 E:600 ||| VB
significantly  ||| S:600 E:614 ||| RB
accurate  ||| S:614 E:623 ||| JJ
and  ||| S:623 E:627 ||| CC
consistent  ||| S:627 E:638 ||| JJ
phenotype  ||| S:638 E:648 ||| JJ
discrimination  ||| S:648 E:663 ||| NN
across  ||| S:663 E:670 ||| IN
a  ||| S:670 E:672 ||| DT
series  ||| S:672 E:679 ||| NN
of  ||| S:679 E:682 ||| IN
omics  ||| S:682 E:688 ||| JJ
data ||| S:688 E:692 ||| NNS
.  ||| S:692 E:694 ||| .
Our  ||| S:694 E:698 ||| PRP$
algorithm  ||| S:698 E:708 ||| NN
can  ||| S:708 E:712 ||| MD
capture  ||| S:712 E:720 ||| VB
those  ||| S:720 E:726 ||| DT
features  ||| S:726 E:735 ||| NNS
contributing  ||| S:735 E:748 ||| VBG
to  ||| S:748 E:751 ||| TO
subtle  ||| S:751 E:758 ||| JJ
data  ||| S:758 E:763 ||| NNS
behaviors  ||| S:763 E:773 ||| VBP
instead  ||| S:773 E:781 ||| RB
of  ||| S:781 E:784 ||| IN
selecting  ||| S:784 E:794 ||| VBG
the  ||| S:794 E:798 ||| DT
features  ||| S:798 E:807 ||| NNS
contributing  ||| S:807 E:820 ||| VBG
to  ||| S:820 E:823 ||| TO
global  ||| S:823 E:830 ||| JJ
data  ||| S:830 E:835 ||| NN
behaviors ||| S:835 E:844 ||| NN
,  ||| S:844 E:846 ||| ,
which  ||| S:846 E:852 ||| WDT
seems  ||| S:852 E:858 ||| VBZ
to  ||| S:858 E:861 ||| TO
be  ||| S:861 E:864 ||| VB
essential  ||| S:864 E:874 ||| JJ
in  ||| S:874 E:877 ||| IN
achieving  ||| S:877 E:887 ||| VBG
clinical  ||| S:887 E:896 ||| JJ
level  ||| S:896 E:902 ||| NN
diagnosis  ||| S:902 E:912 ||| NN
for  ||| S:912 E:916 ||| IN
different  ||| S:916 E:926 ||| JJ
expression  ||| S:926 E:937 ||| NN
data ||| S:937 E:941 ||| NNS
.  ||| S:941 E:943 ||| .
Furthermore ||| S:943 E:954 ||| RB
,  ||| S:954 E:956 ||| ,
as  ||| S:956 E:959 ||| IN
an  ||| S:959 E:962 ||| DT
effective  ||| S:962 E:972 ||| JJ
biomarker  ||| S:972 E:982 ||| JJ
discovery  ||| S:982 E:992 ||| NN
algorithm ||| S:992 E:1001 ||| NN
,  ||| S:1001 E:1003 ||| ,
it  ||| S:1003 E:1006 ||| PRP
can  ||| S:1006 E:1010 ||| MD
achieve  ||| S:1010 E:1018 ||| VB
linear  ||| S:1018 E:1025 ||| JJ
separation  ||| S:1025 E:1036 ||| NN
for  ||| S:1036 E:1040 ||| IN
high-dimensional  ||| S:1040 E:1057 ||| JJ
omics  ||| S:1057 E:1063 ||| JJ
data  ||| S:1063 E:1068 ||| NNS
with  ||| S:1068 E:1073 ||| IN
few  ||| S:1073 E:1077 ||| JJ
biomarkers ||| S:1077 E:1087 ||| NN
.  ||| S:1087 E:1089 ||| .
We  ||| S:1089 E:1092 ||| PRP
apply  ||| S:1092 E:1098 ||| VB
our  ||| S:1098 E:1102 ||| PRP$
MRT-test  ||| S:1102 E:1111 ||| JJ
to  ||| S:1111 E:1114 ||| TO
complex  ||| S:1114 E:1122 ||| JJ
disease  ||| S:1122 E:1130 ||| NN
phenotype  ||| S:1130 E:1140 ||| NN
diagnosis  ||| S:1140 E:1150 ||| NN
by  ||| S:1150 E:1153 ||| IN
combining  ||| S:1153 E:1163 ||| VBG
it  ||| S:1163 E:1166 ||| PRP
with  ||| S:1166 E:1171 ||| IN
state-of-the-art  ||| S:1171 E:1188 ||| JJ
classifiers  ||| S:1188 E:1200 ||| NN
and  ||| S:1200 E:1204 ||| CC
attain  ||| S:1204 E:1211 ||| VB
exceptional  ||| S:1211 E:1223 ||| JJ
diagnostic  ||| S:1223 E:1234 ||| JJ
results ||| S:1234 E:1241 ||| NNS
,  ||| S:1241 E:1243 ||| ,
which  ||| S:1243 E:1249 ||| WDT
suggests  ||| S:1249 E:1258 ||| VBZ
that  ||| S:1258 E:1263 ||| IN
our  ||| S:1263 E:1267 ||| PRP$
method ||| S:1267 E:1273 ||| NN
's  ||| S:1273 E:1276 ||| POS
advantage  ||| S:1276 E:1286 ||| NN
in  ||| S:1286 E:1289 ||| IN
molecular  ||| S:1289 E:1299 ||| JJ
diagnostics ||| S:1299 E:1310 ||| NNS
.  ||| S:1310 E:1312 ||| .
Experimental  ||| S:1312 E:1325 ||| JJ
evaluation  ||| S:1325 E:1336 ||| NN
showed  ||| S:1336 E:1343 ||| VBD
that  ||| S:1343 E:1348 ||| DT
MRT-test  ||| S:1348 E:1357 ||| JJ
based  ||| S:1357 E:1363 ||| VBN
diagnosis  ||| S:1363 E:1373 ||| NN
is  ||| S:1373 E:1376 ||| VBZ
able  ||| S:1376 E:1381 ||| JJ
to  ||| S:1381 E:1384 ||| TO
generate  ||| S:1384 E:1393 ||| VB
consistent  ||| S:1393 E:1404 ||| JJ
and  ||| S:1404 E:1408 ||| CC
robust  ||| S:1408 E:1415 ||| JJ
clinical-level  ||| S:1415 E:1430 ||| JJ
phenotype  ||| S:1430 E:1440 ||| JJ
separation  ||| S:1440 E:1451 ||| NN
for  ||| S:1451 E:1455 ||| IN
various  ||| S:1455 E:1463 ||| JJ
diseases ||| S:1463 E:1471 ||| NNS
.  ||| S:1471 E:1473 ||| .
In  ||| S:1473 E:1476 ||| IN
addition ||| S:1476 E:1484 ||| NN
,  ||| S:1484 E:1486 ||| ,
based  ||| S:1486 E:1492 ||| VBN
on  ||| S:1492 E:1495 ||| IN
the  ||| S:1495 E:1499 ||| DT
seed  ||| S:1499 E:1504 ||| NN
biomarkers  ||| S:1504 E:1515 ||| VBZ
detected  ||| S:1515 E:1524 ||| VBN
by  ||| S:1524 E:1527 ||| IN
the  ||| S:1527 E:1531 ||| DT
MRT-test ||| S:1531 E:1539 ||| JJ
,  ||| S:1539 E:1541 ||| ,
we  ||| S:1541 E:1544 ||| PRP
design  ||| S:1544 E:1551 ||| VB
a  ||| S:1551 E:1553 ||| DT
novel  ||| S:1553 E:1559 ||| NN
network  ||| S:1559 E:1567 ||| NN
marker  ||| S:1567 E:1574 ||| NN
synthesis  ||| S:1574 E:1584 ||| NNS
( ||| S:1584 E:1585 ||| -LRB-
NMS ||| S:1585 E:1588 ||| NNP
)  ||| S:1588 E:1590 ||| -RRB-
algorithm  ||| S:1590 E:1600 ||| NN
to  ||| S:1600 E:1603 ||| TO
decipher  ||| S:1603 E:1612 ||| VB
the  ||| S:1612 E:1616 ||| DT
underlying  ||| S:1616 E:1627 ||| JJ
molecular  ||| S:1627 E:1637 ||| JJ
mechanisms  ||| S:1637 E:1648 ||| NNS
of  ||| S:1648 E:1651 ||| IN
tumorigenesis  ||| S:1651 E:1665 ||| NN
from  ||| S:1665 E:1670 ||| IN
a  ||| S:1670 E:1672 ||| DT
systems  ||| S:1672 E:1680 ||| NNS
viewpoint ||| S:1680 E:1689 ||| NN
.  ||| S:1689 E:1691 ||| .
Unlike  ||| S:1691 E:1698 ||| IN
existing  ||| S:1698 E:1707 ||| VBG
top-down  ||| S:1707 E:1716 ||| JJ
gene  ||| S:1716 E:1721 ||| NN
network  ||| S:1721 E:1729 ||| NN
building  ||| S:1729 E:1738 ||| NN
approaches ||| S:1738 E:1748 ||| NNS
,  ||| S:1748 E:1750 ||| ,
our  ||| S:1750 E:1754 ||| PRP$
network  ||| S:1754 E:1762 ||| NN
marker  ||| S:1762 E:1769 ||| VBZ
synthesis  ||| S:1769 E:1779 ||| JJ
method  ||| S:1779 E:1786 ||| NN
has  ||| S:1786 E:1790 ||| VBZ
a  ||| S:1790 E:1792 ||| DT
less  ||| S:1792 E:1797 ||| JJR
dependence  ||| S:1797 E:1808 ||| NN
on  ||| S:1808 E:1811 ||| IN
the  ||| S:1811 E:1815 ||| DT
global  ||| S:1815 E:1822 ||| JJ
network  ||| S:1822 E:1830 ||| NN
and  ||| S:1830 E:1834 ||| CC
enables  ||| S:1834 E:1842 ||| VBZ
it  ||| S:1842 E:1845 ||| PRP
to  ||| S:1845 E:1848 ||| TO
capture  ||| S:1848 E:1856 ||| VB
the  ||| S:1856 E:1860 ||| DT
gene  ||| S:1860 E:1865 ||| NN
regulators  ||| S:1865 E:1876 ||| NNS
for  ||| S:1876 E:1880 ||| IN
different  ||| S:1880 E:1890 ||| JJ
subnetwork  ||| S:1890 E:1901 ||| JJ
markers ||| S:1901 E:1908 ||| NN
,  ||| S:1908 E:1910 ||| ,
which  ||| S:1910 E:1916 ||| WDT
will  ||| S:1916 E:1921 ||| MD
provide  ||| S:1921 E:1929 ||| VB
biologically  ||| S:1929 E:1942 ||| JJ
meaningful  ||| S:1942 E:1953 ||| JJ
insights  ||| S:1953 E:1962 ||| NNS
for  ||| S:1962 E:1966 ||| IN
understanding  ||| S:1966 E:1980 ||| VBG
the  ||| S:1980 E:1984 ||| DT
genetic  ||| S:1984 E:1992 ||| JJ
basis  ||| S:1992 E:1998 ||| NN
of  ||| S:1998 E:2001 ||| IN
complex  ||| S:2001 E:2009 ||| JJ
diseases ||| S:2009 E:2017 ||| NNS
.  ||| S:2017 E:2019 ||| .
